Potential conflict of interest: M.H., J.D., R.S.D., E.M.: no conflicts of interest to declare. A.T.: Research/grant support, Merck, Roche, Gilead; Consulting/ advisory capacity, Merck, Roche, Janssen-Cilag (Johnson and Johnson), Gilead, Novartis; Speaker's fee, Merck, Roche, Bristol-Myers Squibb, Bayer, Janssen, Gilead. Coinventor of a patent related to the IL28B-HCV discovery.
M.H., J.D., R.S.D., A.T., and E.M. are supported by the National Health and Medical Research Council. J.D. and R.S.D. are supported by the NHMRC-funded Centre for Research Excellence into Injecting Drug Use. The authors acknowledge the contribution to this work of the Victorian Operational Infrastructure Support Program (Department of Health, Victoria, Australia) to the Burnet Institute.